{
    "clinical_study": {
        "@rank": "5076", 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection\n      in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have\n      demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or\n      parenteral pentamidine)."
        }, 
        "brief_title": "A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive intravenous infusions of trimetrexate glucuronate and leucovorin for 21\n      days. Leucovorin is continued for 3 additional days after discontinuation of trimetrexate\n      glucuronate. Patients are followed for 1 month."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Pneumocystis carinii pneumonia (PCP) confirmed within 15 days prior to study entry.\n\n          -  Serious intolerance and/or resistance to standard therapies (such as\n             trimethoprim/sulfamethoxazole and parenteral pentamidine) during the course of\n             therapy for the current episode of PCP, OR a documented history of such intolerance\n             during a prior episode.\n\n          -  Consent of parent or guardian if less than 18 years of age.\n\n        Exclusion Criteria\n\n        Patients with the following prior conditions are excluded:\n\n        History of Type I hypersensitivity (i.e., urticaria, angioedema, or anaphylaxis),\n        exfoliative dermatitis, or other life-threatening reactions due to trimetrexate\n        glucuronate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002103", 
            "org_study_id": "132C", 
            "secondary_id": "TMTX C502"
        }, 
        "intervention": [
            {
                "intervention_name": "Trimetrexate glucuronate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Leucovorin calcium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin", 
                "Trimetrexate"
            ]
        }, 
        "keyword": [
            "Trimetrexate", 
            "Pneumonia, Pneumocystis carinii", 
            "Leucovorin", 
            "Drug Therapy, Combination", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "West Conshohocken", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19428"
                }, 
                "name": "United States Bioscience Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "reference": {
            "citation": "Feinberg J, McDermott C, Nutter J. Trimetrexate (TMTX) salvage therapy for PCP in AIDS patients with limited therapeutic options. Int Conf AIDS. 1992 Jul 19-24;8(2):B136 (abstract no PoB 3297)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002103"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "U.S. Bioscience", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1994"
    }, 
    "geocoordinates": {
        "United States Bioscience Inc": "40.07 -75.316"
    }
}